Developer docs
API playgroundTry for free, no card

Search company profiles

InventisBio

Full company profile

uuid0000ynq

Namestring
InventisBio
Legal namestring
益方生物科技(上海)股份有限公司
Websiteurl
inventisbio.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

InventisBio (益方生物科技(上海)股份有限公司) is a Shanghai-headquartered, publicly listed (SSE STAR Market: 688382) clinical- and early-commercial-stage biotechnology company developing self-discovered small-molecule therapeutics for oncology, autoimmune diseases, and metabolic disorders. Founded in 2013 by Dr. Yaolin Wang and a team of ex-Merck and Schering-Plough scientists, the company operates a structure-based drug design platform that has produced a pipeline of internally developed kinase inhibitors, oral SERDs, and synthetic-lethality candidates. Its most advanced asset, Garsorasib (D-1553 / Anfangning), is a highly selective oral KRAS G12C inhibitor that received NMPA approval in November 2024 for KRAS G12C-mutant advanced NSCLC and is being expanded into pancreatic and colorectal cancer indications; additional clinical-stage assets include D-2570 (TYK2 JH2 inhibitor, Phase III for psoriasis), D-0502/taragarestrant (oral SERD, Phase III for HR+/HER2- breast cancer), and D-0120/darbinurad (URAT1 inhibitor for hyperuricemia, Phase IIb completed).

The company makes money primarily through licensing and milestone payments from commercial partners, supplemented by nascent product sales. Garsorasib is commercialized in mainland China under an exclusive license with Chia Tai Tianqing (CTTQ), which handles development, registration, production, and commercialization — InventisBio receives milestones and royalties. The earlier EGFR-T790M inhibitor D-0316 was out-licensed to Betta Pharmaceuticals for Greater China rights in exchange for 230 million RMB in upfront and milestone payments plus royalties. The company has not disclosed product pricing, and ex-China commercial rights for Garsorasib remain unpartnered. Headquartered in Shanghai's Zhangjiang Pharma Valley with additional R&D operations in Beijing and a US clinical/regulatory presence in New Jersey, InventisBio is led by its founder-Chairman-CEO and a senior team averaging over 20 years of big-pharma R&D experience, including leadership roles on Merck's Keytruda program.

Short descriptiontext

InventisBio is a Shanghai-listed, clinical- and early-commercial-stage Chinese biotech developing self-discovered small-molecule drugs for oncology, autoimmune, and metabolic diseases, with two approved products and two Phase III assets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small-molecule drug discovery, targeted oncology therapeutics, kinase inhibitor development, autoimmune disease treatments, clinical-stage biopharmaceuticals
Industry3 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Targeted Small-Molecule Oncology and Immunology Therapeutics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Drug Sales and Commercialization
TypeOne Time License
Description

InventisBio generates revenue through the sale of approved drugs. The company has two approved drugs: Anfangning (Garsorasib/D-1553, KRAS G12C inhibitor for NSCLC) was approved by NMPA in November 2024 and shipped nationally in December 2024. Revenue is also generated through licensing and milestone payments from commercial partners. Garsorasib is commercialized in mainland China by Chia Tai Tianqing (正大天晴) under an exclusive license agreement, with InventisBio receiving milestone and potential royalty payments.

inventisbio.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

InventisBio earns revenue through upfront payments, development milestones, regulatory milestones, and sales royalties from licensing agreements. The D-0316 (EGFR T790M inhibitor) deal with Betta Pharmaceuticals generated 230 million RMB in upfront and development milestones plus sales milestones and royalties. The Garsorasib deal with Chia Tai Tianqing includes development, registration, and commercialization milestones plus sales royalties.

inventisbio.com
3Collaborative Development Revenue
TypeProfessional Services
Description

The company participates in co-development arrangements where partners fund clinical development costs in exchange for regional commercialization rights, generating non-dilutive capital to support ongoing R&D programs across the pipeline.

inventisbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1安方宁 (Anfangning)
Description

Brand name for Garsorasib (格索雷塞, D-1553), a KRAS G12C inhibitor approved by NMPA in November 2024 for treatment of KRAS G12C-mutant NSCLC.

inventisbio.com
Core offering1 text field

InventisBio discovers, develops, and commercializes innovative small-molecule drugs for oncology, autoimmune diseases, and metabolic disorders. The company has two approved drugs on the market — Garsorasib (D-1553, brand Anfangning), an oral KRAS G12C inhibitor approved by NMPA in November 2024 for KRAS G12C-mutant NSCLC, and D-0316 (licensed to Betta Pharmaceuticals) — alongside three candidates in clinical trials (D-2570 and D-0502 in Phase III registration trials; D-0120 with Phase IIb completed) and preclinical programs targeting WRN, KIF18A, and STAT6.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Garsorasib achieved ORR of 52% and DCR of 88.6% in 123 KRAS G12C-mutant NSCLC patients; median PFS 9.1 months, median OS 14.1 months (Phase II, May 2024 data)
+4 more records
Product overview1 text field

InventisBio is a clinical-stage biotech company with two approved drugs. The company's clinical-stage pipeline centers on four key products: TYK2 inhibitor D-2570 (Nomelcitinib) and oral SERD Taragarestrant (D-0502) are both advancing through Phase III registration trials; URAT1 inhibitor Darbinurad (D-0120) has completed Phase IIb; and KRAS G12C inhibitor Garsorasib/Anfangning (D-1553) received NMPA approval in November 2024 for NSCLC and is being developed for additional indications. The preclinical pipeline includes WRN inhibitor YF087, KIF18A inhibitor YF550, and oral STAT6 degrader YF057. The company maintains partnerships with Chia Tai Tianqing (CTTQ) for Garsorasib commercialization in mainland China and Beta Pharma for EGFR-T790M inhibitor BPI-D0316.

Product and service8 records
1Garsorasib (D-1553, 安方宁/Anfangning)
CategoryTargeted oncology therapy (kinase inhibitor)
Description

Novel oral KRAS G12C inhibitor approved by China's NMPA in November 2024 for KRAS G12C-mutant non-small cell lung cancer (NSCLC), with additional indications in development for colorectal cancer (in combination with cetuximab) and pancreatic cancer. Bicyclic cyclopropyl-substituted piperazine scaffold provides high selectivity and irreversible binding at the SWITCH II pocket. Commercialized in mainland China via exclusive license with Chia Tai Tianqing Pharmaceutical Group (正大天晴药业集团).

2Taragarestrant (D-0502)
CategoryTargeted oncology therapy (hormone receptor degrader)
Description

Oral selective estrogen receptor degrader (SERD) in Phase III registration trials for ER-positive, HER2-negative breast cancer, including patients with ESR1 mutations and those progressing after CDK4/6 inhibitor and endocrine therapy. Offers an oral outpatient alternative to injectable fulvestrant with high bioavailability and favorable pharmacokinetics.

3Nomelcitinib (D-2570)
CategoryImmunology / autoimmune therapy (TYK2 inhibitor)
Description

Selective oral TYK2 inhibitor targeting the JH2 pseudokinase domain with approximately 1000-fold selectivity over JAK1, suggesting a wider safety window than broad-spectrum JAK inhibitors. In Phase III registration trials for moderate-to-severe plaque psoriasis and Phase II for active ulcerative colitis. Phase II psoriasis data showed PASI 75 response of 85-90% vs 12.5% placebo at Week 12 with PASI 100 reaching 50% at high dose.

4Darbinurad (D-0120)
CategoryMetabolic disease therapy (URAT1 inhibitor)
Description

URAT1 inhibitor for the treatment of hyperuricemia and chronic gout in patients who are unresponsive to standard urate-lowering therapies such as xanthine oxidase inhibitors. Completed Phase IIb clinical trial.

5D-0316 (BPI-D0316)
CategoryTargeted oncology therapy (EGFR-T790M inhibitor)
Description

Third-generation EGFR-T790M tyrosine kinase inhibitor for EGFR-mutant non-small cell lung cancer, advanced to Phase II registration trials under license partner Betta Pharmaceuticals (贝达药业). Generates revenue for InventisBio via upfront, milestone, and royalty payments.

6YF087 (WRN helicase inhibitor)
CategoryTargeted oncology therapy (synthetic lethal / WRN inhibitor)
Description

Highly selective WRN (Werner syndrome helicase) inhibitor targeting synthetic lethal dependency in MSI-H tumors including endometrial, gastric, colorectal, and ovarian cancers. Currently in preclinical development.

7YF550 (KIF18A inhibitor)
CategoryTargeted oncology therapy (KIF18A / kinesin inhibitor)
Description

KIF18A (kinesin-18 family) small-molecule inhibitor targeting chromosomal instability (CIN) and aneuploidy tumors critical for tumor cell division. Being developed for solid tumors including ovarian, triple-negative breast, colorectal, and lung cancers. Currently in preclinical development.

8YF057 (oral STAT6 degrader)
CategoryImmunology / autoimmune therapy (STAT6 degrader)
Description

Oral STAT6 protein degrader targeting the STAT6 signaling pathway for autoimmune and inflammatory diseases. Currently in preclinical development.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Combination therapy collaboration for D-0502 (oral SERD) with JSKN016 (Alphamab's TROP2/HER3 bispecific ADC). NMPA IND approved December 2025 for treatment of locally advanced or metastatic HR+/HER2- breast cancer. First clinical exploration of oral SERD + ADC combination therapy.

2Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (正大天晴药业集团股份有限公司)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-08-01
Description

InventisBio entered into an exclusive License and Collaboration Agreement with Chia Tai Tianqing (CTTQ Pharma) in August 2023 for Garsorasib (D-1553/Anfangning). InventisBio granted CTTQ exclusive rights for development, registration, production, and commercialization of Garsorasib in mainland China. InventisBio retained rights outside China. The drug was approved by NMPA on November 8, 2024 and CTTQ handled first nationwide shipment in December 2024.

inventisbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-07
Description

Global strategic collaboration for combination therapy development. InventisBio's KRAS G12C inhibitor D-1553 (Garsorasib) combined with Inxite Medical's FAK inhibitor IN10018 for oncology indications. Preclinical studies showed tumor cells develop resistance to KRAS G12C inhibitors via FAK activation, and the combination demonstrated synergistic anti-tumor effects in lung and colorectal cancer models.

4Betta Pharmaceuticals Co., Ltd. (贝达药业股份有限公司)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-12-28
Description

InventisBio transferred China rights (mainland China, Hong Kong, Taiwan) for D-0316 (BPI-D0316, third-generation EGFR-T790M tyrosine kinase inhibitor) to Betta Pharmaceuticals. Betta holds exclusive rights for development and commercialization in the licensed region. InventisBio received upfront and milestone payments totaling 230 million RMB plus sales milestones and royalties. D-0316 advanced to Phase II registration trials for EGFR-mutant NSCLC.

inventisbio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of Krazati (adagrasib), a competing KRAS G12C inhibitor approved for NSCLC. Acquired by Bristol-Myers Squibb in 2024 for $4.8B. Most direct peer in terms of targeting the same KRAS G12C mutation with similar patient populations and clinical positioning.

TypeBroad incumbent
Description

Leading Chinese biotech with multiple approved biologic drugs (sintilimab, etc.) and strong partnership with Eli Lilly. While focused on biologics rather than small molecules, comparable as a major Chinese innovative drug developer with both domestic and international operations.

TypeDirect peer
Description

Clinical-stage oncology company developing RAS(ON) inhibitors including RMC-6236 (pan-RAS) and RMC-6291 (KRAS G12C). Directly competes with InventisBio's Garsorasib in KRAS G12C space and represents next-generation approach that could obsolete selective inhibitors.

TypeEmerging player
Description

US clinical-stage biotech focused on genetic disease and targeted oncology with similar pipeline approach of advancing internally discovered small molecules. Comparable in company stage and R&D focus, though with different therapeutic area mix.

TypeBroad incumbent
Description

Largest Chinese oncology biotech by market cap with approved Brukinsa (zanubrutinib). Significantly larger and more diversified across hematology and solid tumors, but shares the China-origin innovative drug developer profile with global commercialization ambitions.

6Hutchmed (China) Limited
TypeDirect peer
Description

Hong Kong-listed Chinese clinical-stage biotech with multiple approved oncology drugs (surufatinib, fruquintinib, savolitinib) and similar structure-based drug discovery approach. Comparable in scale, business model, and focus on targeted oncology therapies for both China and global markets.

TypeDirect peer
Description

Shanghai-based clinical-stage biotech with approved precision oncology drugs (sugemalimab, avapritinib in China). Similar business model of discovering/licensing targeted oncology therapies for China market with focus on KRAS and other difficult targets.

TypeBroad incumbent
Description

Shanghai-based Chinese biotech with approved PD-1 inhibitor (toripalimab) and broad oncology pipeline. Similar profile to InventisBio as a Shanghai-headquartered Chinese clinical-stage company with STAR Market or HKEX listing and multiple pipeline assets.

TypeEmerging player
Description

Emerging clinical-stage company developing firmonertinib (EGFR exon 20) and other targeted oncology therapies. Smaller and earlier-stage than InventisBio but focused on similar targeted oncology space with China-origin assets and US operations.

10Betta Pharmaceuticals
TypeRegional player
Description

Chinese specialty oncology company that holds China rights to InventisBio's D-0316 (EGFR-T790M inhibitor) under a 230M RMB licensing deal. A direct commercial partner and peer in the China targeted oncology space, with overlapping product portfolios.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InventisBio

Targeted Small-Molecule Oncology and Immunology Therapeuticsinventisbio.com

InventisBio is a Shanghai-listed, clinical- and early-commercial-stage Chinese biotech developing self-discovered small-molecule drugs for oncology, autoimmune, and metabolic diseases, with two approved products and two Phase III assets.

What InventisBio does

InventisBio (益方生物科技(上海)股份有限公司) is a Shanghai-headquartered, publicly listed (SSE STAR Market: 688382) clinical- and early-commercial-stage biotechnology company developing self-discovered small-molecule therapeutics for oncology, autoimmune diseases, and metabolic disorders. Founded in 2013 by Dr. Yaolin Wang and a team of ex-Merck and Schering-Plough scientists, the company operates a structure-based drug design platform that has produced a pipeline of internally developed kinase inhibitors, oral SERDs, and synthetic-lethality candidates. Its most advanced asset, Garsorasib (D-1553 / Anfangning), is a highly selective oral KRAS G12C inhibitor that received NMPA approval in November 2024 for KRAS G12C-mutant advanced NSCLC and is being expanded into pancreatic and colorectal cancer indications; additional clinical-stage assets include D-2570 (TYK2 JH2 inhibitor, Phase III for psoriasis), D-0502/taragarestrant (oral SERD, Phase III for HR+/HER2- breast cancer), and D-0120/darbinurad (URAT1 inhibitor for hyperuricemia, Phase IIb completed).

The company makes money primarily through licensing and milestone payments from commercial partners, supplemented by nascent product sales. Garsorasib is commercialized in mainland China under an exclusive license with Chia Tai Tianqing (CTTQ), which handles development, registration, production, and commercialization — InventisBio receives milestones and royalties. The earlier EGFR-T790M inhibitor D-0316 was out-licensed to Betta Pharmaceuticals for Greater China rights in exchange for 230 million RMB in upfront and milestone payments plus royalties. The company has not disclosed product pricing, and ex-China commercial rights for Garsorasib remain unpartnered. Headquartered in Shanghai's Zhangjiang Pharma Valley with additional R&D operations in Beijing and a US clinical/regulatory presence in New Jersey, InventisBio is led by its founder-Chairman-CEO and a senior team averaging over 20 years of big-pharma R&D experience, including leadership roles on Merck's Keytruda program.

InventisBio firmographics

Firmographics
Name
InventisBio
Legal name
益方生物科技(上海)股份有限公司
Website
https://inventisbio.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
InventisBio is a Shanghai-listed, clinical- and early-commercial-stage Chinese biotech developing self-discovered small-molecule drugs for oncology, autoimmune, and metabolic diseases, with two approved products and two Phase III assets.
Ownership category
akta.pro rank

InventisBio industry classification

Industry
Product category
Targeted Small-Molecule Oncology and Immunology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Small-molecule drug discovery
  • Targeted oncology therapeutics
  • Kinase inhibitor development
  • Autoimmune disease treatments
  • Clinical-stage biopharmaceuticals

Where InventisBio is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices3 records

Markets served

InventisBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Sales and Commercialization: InventisBio generates revenue through the sale of approved drugs. The company has two approved drugs: Anfangning (Garsorasib/D-1553, KRAS G12C inhibitor for NSCLC) was approved by NMPA in November 2024 and shipped nationally in December 2024. Revenue is also generated through licensing and milestone payments from commercial partners. Garsorasib is commercialized in mainland China by Chia Tai Tianqing (正大天晴) under an exclusive license agreement, with InventisBio receiving milestone and potential royalty payments.
  2. Licensing and Milestone Payments: InventisBio earns revenue through upfront payments, development milestones, regulatory milestones, and sales royalties from licensing agreements. The D-0316 (EGFR T790M inhibitor) deal with Betta Pharmaceuticals generated 230 million RMB in upfront and development milestones plus sales milestones and royalties. The Garsorasib deal with Chia Tai Tianqing includes development, registration, and commercialization milestones plus sales royalties.
  3. Collaborative Development Revenue: The company participates in co-development arrangements where partners fund clinical development costs in exchange for regional commercialization rights, generating non-dilutive capital to support ongoing R&D programs across the pipeline.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

InventisBio product offering

Product offering

Core offering

InventisBio discovers, develops, and commercializes innovative small-molecule drugs for oncology, autoimmune diseases, and metabolic disorders. The company has two approved drugs on the market — Garsorasib (D-1553, brand Anfangning), an oral KRAS G12C inhibitor approved by NMPA in November 2024 for KRAS G12C-mutant NSCLC, and D-0316 (licensed to Betta Pharmaceuticals) — alongside three candidates in clinical trials (D-2570 and D-0502 in Phase III registration trials; D-0120 with Phase IIb completed) and preclinical programs targeting WRN, KIF18A, and STAT6.

Product overview

InventisBio is a clinical-stage biotech company with two approved drugs. The company's clinical-stage pipeline centers on four key products: TYK2 inhibitor D-2570 (Nomelcitinib) and oral SERD Taragarestrant (D-0502) are both advancing through Phase III registration trials; URAT1 inhibitor Darbinurad (D-0120) has completed Phase IIb; and KRAS G12C inhibitor Garsorasib/Anfangning (D-1553) received NMPA approval in November 2024 for NSCLC and is being developed for additional indications. The preclinical pipeline includes WRN inhibitor YF087, KIF18A inhibitor YF550, and oral STAT6 degrader YF057. The company maintains partnerships with Chia Tai Tianqing (CTTQ) for Garsorasib commercialization in mainland China and Beta Pharma for EGFR-T790M inhibitor BPI-D0316.

Differentiator

Problem solved

Functional benefit

Brands

  • 安方宁 (Anfangning): Brand name for Garsorasib (格索雷塞, D-1553), a KRAS G12C inhibitor approved by NMPA in November 2024 for treatment of KRAS G12C-mutant NSCLC.

Products and services

  • Garsorasib (D-1553, 安方宁/Anfangning) Novel oral KRAS G12C inhibitor approved by China's NMPA in November 2024 for KRAS G12C-mutant non-small cell lung cancer (NSCLC), with additional indications in development for colorectal cancer (in combination with cetuximab) and pancreatic cancer. Bicyclic cyclopropyl-substituted piperazine scaffold provides high selectivity and irreversible binding at the SWITCH II pocket. Commercialized in mainland China via exclusive license with Chia Tai Tianqing Pharmaceutical Group (正大天晴药业集团).
  • Taragarestrant (D-0502) Oral selective estrogen receptor degrader (SERD) in Phase III registration trials for ER-positive, HER2-negative breast cancer, including patients with ESR1 mutations and those progressing after CDK4/6 inhibitor and endocrine therapy. Offers an oral outpatient alternative to injectable fulvestrant with high bioavailability and favorable pharmacokinetics.
  • Nomelcitinib (D-2570) Selective oral TYK2 inhibitor targeting the JH2 pseudokinase domain with approximately 1000-fold selectivity over JAK1, suggesting a wider safety window than broad-spectrum JAK inhibitors. In Phase III registration trials for moderate-to-severe plaque psoriasis and Phase II for active ulcerative colitis. Phase II psoriasis data showed PASI 75 response of 85-90% vs 12.5% placebo at Week 12 with PASI 100 reaching 50% at high dose.
  • Darbinurad (D-0120) URAT1 inhibitor for the treatment of hyperuricemia and chronic gout in patients who are unresponsive to standard urate-lowering therapies such as xanthine oxidase inhibitors. Completed Phase IIb clinical trial.
  • D-0316 (BPI-D0316) Third-generation EGFR-T790M tyrosine kinase inhibitor for EGFR-mutant non-small cell lung cancer, advanced to Phase II registration trials under license partner Betta Pharmaceuticals (贝达药业). Generates revenue for InventisBio via upfront, milestone, and royalty payments.
  • YF087 (WRN helicase inhibitor) Highly selective WRN (Werner syndrome helicase) inhibitor targeting synthetic lethal dependency in MSI-H tumors including endometrial, gastric, colorectal, and ovarian cancers. Currently in preclinical development.
  • YF550 (KIF18A inhibitor) KIF18A (kinesin-18 family) small-molecule inhibitor targeting chromosomal instability (CIN) and aneuploidy tumors critical for tumor cell division. Being developed for solid tumors including ovarian, triple-negative breast, colorectal, and lung cancers. Currently in preclinical development.
  • YF057 (oral STAT6 degrader) Oral STAT6 protein degrader targeting the STAT6 signaling pathway for autoimmune and inflammatory diseases. Currently in preclinical development.

Quantifiable outcome

  • Garsorasib achieved ORR of 52% and DCR of 88.6% in 123 KRAS G12C-mutant NSCLC patients; median PFS 9.1 months, median OS 14.1 months (Phase II, May 2024 data)
  • +4 more outcomes

Companies that use InventisBio

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

InventisBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

InventisBio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Alphamab Oncology (康宁杰瑞生物制药)coreStrategic or Co-development Partner · 22 December 2025Combination therapy collaboration for D-0502 (oral SERD) with JSKN016 (Alphamab's TROP2/HER3 bispecific ADC). NMPA IND approved December 2025 for treatment of locally advanced or metastatic HR+/HER2- breast cancer. First clinical exploration of oral SERD + ADC combination therapy.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (正大天晴药业集团股份有限公司)coreChannel Partner/ Reseller/ Distributor · 1 August 2023InventisBio entered into an exclusive License and Collaboration Agreement with Chia Tai Tianqing (CTTQ Pharma) in August 2023 for Garsorasib (D-1553/Anfangning). InventisBio granted CTTQ exclusive rights for development, registration, production, and commercialization of Garsorasib in mainland China. InventisBio retained rights outside China. The drug was approved by NMPA on November 8, 2024 and CTTQ handled first nationwide shipment in December 2024.
  • Inxite Medical (应世生物科技(南京)有限公司)coreStrategic or Co-development Partner · 7 September 2021Global strategic collaboration for combination therapy development. InventisBio's KRAS G12C inhibitor D-1553 (Garsorasib) combined with Inxite Medical's FAK inhibitor IN10018 for oncology indications. Preclinical studies showed tumor cells develop resistance to KRAS G12C inhibitors via FAK activation, and the combination demonstrated synergistic anti-tumor effects in lung and colorectal cancer models.
  • Betta Pharmaceuticals Co., Ltd. (贝达药业股份有限公司)coreTechnology or Integration · 28 December 2018InventisBio transferred China rights (mainland China, Hong Kong, Taiwan) for D-0316 (BPI-D0316, third-generation EGFR-T790M tyrosine kinase inhibitor) to Betta Pharmaceuticals. Betta holds exclusive rights for development and commercialization in the licensed region. InventisBio received upfront and milestone payments totaling 230 million RMB plus sales milestones and royalties. D-0316 advanced to Phase II registration trials for EGFR-mutant NSCLC.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

InventisBio competitors and assessment

Company assessment

Direct peers

  • Mirati Therapeutics: Developer of Krazati (adagrasib), a competing KRAS G12C inhibitor approved for NSCLC. Acquired by Bristol-Myers Squibb in 2024 for $4.8B. Most direct peer in terms of targeting the same KRAS G12C mutation with similar patient populations and clinical positioning.
  • Revolution Medicines: Clinical-stage oncology company developing RAS(ON) inhibitors including RMC-6236 (pan-RAS) and RMC-6291 (KRAS G12C). Directly competes with InventisBio's Garsorasib in KRAS G12C space and represents next-generation approach that could obsolete selective inhibitors.
  • Hutchmed (China) Limited: Hong Kong-listed Chinese clinical-stage biotech with multiple approved oncology drugs (surufatinib, fruquintinib, savolitinib) and similar structure-based drug discovery approach. Comparable in scale, business model, and focus on targeted oncology therapies for both China and global markets.
  • CStone Pharmaceuticals: Shanghai-based clinical-stage biotech with approved precision oncology drugs (sugemalimab, avapritinib in China). Similar business model of discovering/licensing targeted oncology therapies for China market with focus on KRAS and other difficult targets.

Broad incumbents

  • Innovent Biologics: Leading Chinese biotech with multiple approved biologic drugs (sintilimab, etc.) and strong partnership with Eli Lilly. While focused on biologics rather than small molecules, comparable as a major Chinese innovative drug developer with both domestic and international operations.
  • BeiGene: Largest Chinese oncology biotech by market cap with approved Brukinsa (zanubrutinib). Significantly larger and more diversified across hematology and solid tumors, but shares the China-origin innovative drug developer profile with global commercialization ambitions.
  • Junshi Biosciences: Shanghai-based Chinese biotech with approved PD-1 inhibitor (toripalimab) and broad oncology pipeline. Similar profile to InventisBio as a Shanghai-headquartered Chinese clinical-stage company with STAR Market or HKEX listing and multiple pipeline assets.

Emerging players

  • BridgeBio Pharma: US clinical-stage biotech focused on genetic disease and targeted oncology with similar pipeline approach of advancing internally discovered small molecules. Comparable in company stage and R&D focus, though with different therapeutic area mix.
  • Arrivent Biopharma: Emerging clinical-stage company developing firmonertinib (EGFR exon 20) and other targeted oncology therapies. Smaller and earlier-stage than InventisBio but focused on similar targeted oncology space with China-origin assets and US operations.

Regional players

  • Betta Pharmaceuticals: Chinese specialty oncology company that holds China rights to InventisBio's D-0316 (EGFR-T790M inhibitor) under a 230M RMB licensing deal. A direct commercial partner and peer in the China targeted oncology space, with overlapping product portfolios.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

InventisBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InventisBio leadership team

Management profile

Number of profiles

Profiles4 records

InventisBio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InventisBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InventisBio

What does InventisBio do?

InventisBio discovers, develops, and commercializes innovative small-molecule drugs for oncology, autoimmune diseases, and metabolic disorders. The company has two approved drugs on the market — Garsorasib (D-1553, brand Anfangning), an oral KRAS G12C inhibitor approved by NMPA in November 2024 for KRAS G12C-mutant NSCLC, and D-0316 (licensed to Betta Pharmaceuticals) — alongside three candidates in clinical trials (D-2570 and D-0502 in Phase III registration trials; D-0120 with Phase IIb completed) and preclinical programs targeting WRN, KIF18A, and STAT6.

Is InventisBio a public or private company?

InventisBio is a public company. It is classified as public and is currently operating.

When was InventisBio founded?

InventisBio was founded in 2013. It employs 11 to 50 people.

Where is InventisBio based?

InventisBio is headquartered in Shanghai, China, in the Asia region.

How does InventisBio make money?

Three revenue lines are on record. Drug Sales and Commercialization is the primary driver. The others are licensing and Milestone Payments and collaborative Development Revenue.

Who are InventisBio's main competitors?

Direct peers on record are Mirati Therapeutics, Revolution Medicines, Hutchmed (China) Limited and CStone Pharmaceuticals. Broad incumbents are Innovent Biologics, BeiGene and Junshi Biosciences. Emerging players are BridgeBio Pharma and Arrivent Biopharma. Betta Pharmaceuticals is listed as a regional player.

Does InventisBio have an API?

No public API is recorded for InventisBio.

What industry is InventisBio in?

InventisBio's product category is Targeted Small-Molecule Oncology and Immunology Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型InventisBio's Oral TYK2 Inhibitor Hits Best-in-Class Bar in Psoriasis Phase IIIInventisBio reported a Phase III registration-grade win for nomelcitinib in 391 psoriasis patients, with PASI 90 rates above 70% and PGA 0/1 rates above 80% at week 16. The results outperformed placebo and existing comparators, and the company is running a head-to-head trial against deucravacitinib.The Pharma LetterInventisBio's nomelcitinib meets Phase III goals in psoriasisInventisBio reported positive Phase III results for nomelcitinib in moderate-to-severe plaque psoriasis. The registrational study enrolled 391 Chinese patients, and both nomelcitinib groups met the primary endpoint at week 16.FierceBiotechChina's InventisBio delivers competitive TYK2 data in phase 3 psoriasis winInventisBio's nomelcitinib met its primary endpoint in a phase 3 psoriasis trial, with over 70% of patients achieving PASI 90 at Week 16. The rate outperformed rival TYK2 drugs from Takeda and Alumis, and no new safety signals emerged. The company is running another phase 3 trial in China.PR NewswireQiming's Portfolio Company InventisBio Lists on STAR MarketInventisBio, a biotech company focused on innovative drug development, listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange with an issue price of CNY 18.12 per share. The listing values the company at approximately CNY 10.419 billion and marks the fourth IPO in Qiming Venture Partners' portfolio for 2022. This event provides InventisBio with capital to accelerate product industrialization and advance its pipeline of clinical-stage drugs.BioWorldInventisbio reveals $147M series D funding roundShanghai-headquartered Inventisbio Inc. raised $147 million in a series D funding round. The funds will move its main products into phase II trials in the U.S. and China. The round was announced on Oct. 6, 2020.FinSMEsInventisBio Raises $147M in Series D FinancingInventisBio, a Shanghai-based biotech, closed a $147M Series D led by GL Ventures. The funds will support phase II trials in China and the US for its breast cancer drug D-0502 and gout drug D-0120, plus expand its pipeline.China Money NetworkCancer Innovative Drug Startup Inventis Bio Secures Over RMB1 BillionInventis Bio, a cancer drug startup, completed a series D financing of over RMB1 billion. The round was led by Hillhouse Ventures, Qiming Ventures, and Janchor. The financing details are locked behind a paywall.PR Newswire APACInventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL VenturesInventisBio completed a $147 million Series D financing led by Hillhouse affiliate GL Ventures, with participation from other top funds. The company has three drugs in mid- to late-stage clinical development, including D-0502 for breast cancer and BPI-D0316 for lung cancer. Funds will support phase II trials in China and the U.S.https://www.avcj.comChina's InventisBio secures $147m Series DGL Ventures led a $147 million Series D round for Shanghai biotech InventisBio, with participation from Qiming, Matrix, and others. The company will use the funds to advance at least two products into phase-two trials, including breast cancer and gout treatments. It also has four drug candidates in clinical stages.PR NewswireInventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL VenturesInventisBio, a Shanghai-based clinical-stage biotech company focused on innovative small molecule drugs for cancer and metabolic diseases, has completed a $147 million Series D financing round led by Hillhouse affiliate GL Ventures, with participation from Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partner China, Dyee Capital, E Fund Capital, and continued support from existing shareholders including Lilly Asia Venture, OrbiMed Asia, Pudong Innotek, AdvanTech Capital, and CMB International. The funds will support ongoing clinical development including D-0502 for hormone receptor positive breast cancer and D-0120 for gout through Phase II trials in China and the United States, as well as global clinical expansion and pipeline growth. The company currently has three drug candidates in mid-to-late-stage clinical development and one in global Phase I, with programs in oncology and metabolic disease areas.